Navigation Links
Scientists reveal new targets for anti-angiogenesis drugs
Date:8/16/2010

BOSTON (August 16, 2010, 9:00 a.m. EDT) A new study describes how a carbohydrate-binding protein, galectin-3, promotes angiogenesis, the growth of new blood vessels. Targeting the protein, scientists identified two approaches that significantly reduced angiogenesis in mice. These discoveries, published online August 16 in the Journal of Experimental Medicine, may lead to novel treatments for diseases caused by excessive angiogenesis, including age-related macular degeneration, cancer, and diabetes.

When the body needs to expand its network of blood vessels, cells release molecular signals called growth factors that prompt angiogenesis. While this process is key for normal growth, development, and wound healing, it can be harmful when blood vessels supply tumors or other diseased tissue, or when excessive blood vessel growth encroaches on surrounding tissues.

A growing body of research indicates that a protein called galectin-3 promotes angiogenesis, indicating that it may be a valuable target for drugs that halt harmful blood vessel growth. Until now, though, scientists did not understand how galectin-3 promotes angiogenesis.

Led by Noorjahan Panjwani, PhD, researchers propose a mechanism that explains how galectin-3 brings about angiogenesis. Panjwani is a professor in the department of ophthalmology at Tufts University School of Medicine and a member of the biochemistry and cell, molecular and developmental biology program faculties at the Sackler School of Graduate Biomedical Sciences.

"Our study shows that galectin-3 protein binds to glycans (carbohydrate portions) of specific cell-adhesion proteins, the integrins, to activate the signaling pathways that bring about angiogenesis. This improved understanding may provide a more targeted approach to preventing harmful angiogenesis," said Panjwani.

"We found that application of a galectin-3 inhibitor significantly reduced angiogenesis in mice. We also
'/>"/>

Contact: Siobhan Gallagher
617-636-6586
Tufts University, Health Sciences
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells
2. Scientists identify novel inhibitor of human microRNA
3. Argonne scientists peer into heart of compound that may detect chemical, biological weapons
4. MU scientists go green with gold, distribute environmentally friendly nanoparticles
5. Scientists identify gene that may contribute to improved rice yield
6. Scientists discover why a mothers high-fat diet contributes to obesity in her children
7. MU scientists see how HIV matures into an infection
8. Earth scientists keep an eye on Texas
9. Thinking it through: Scientists call for policy to guide biofuels industry toward sustainability
10. Scientists identify a molecule that coordinates the movement of cells
11. Scientists Find new migratory patterns for Mediterranean and Western Atlantic bluefin tuna
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scientists reveal new targets for anti-angiogenesis drugs
(Date:8/26/2015)... 26, 2015 The report "Multi-Factor Authentication ... Factor), Application (Travel & Immigration, Government, Banking, Defense, Commercial ... to 2020", published by MarketsandMarkets, Multi-Factor Authentication Market is ... at a CAGR of 17.7% between 2015 and 2020. ... igures spread through 169 P ...
(Date:8/24/2015)... MOUNTAIN VIEW, Calif. , Aug. 24, 2015  Based ... & Sullivan recognizes DERMALOG with the 2015 African Biometrics Company ... manufacturer and has achieved substantial commercial success in ... Nigeria , where it has implemented one of ... equipped 23 banks as well as the Central Bank of ...
(Date:8/20/2015)... Aug. 20, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market and ... joined The Smart Card Alliance and the EMV Migration ... and the Smart Card Alliance Latin America (SCALA) Chapter ... peers and thought leaders promoting adoption of smart card ...
Breaking Biology News(10 mins):Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4
... issue of the Journal of General Physiology ... evidence that advances previous conclusions about the essential features ... channel. As Richard Horn (Department of Molecular Physiology ... in his JGP commentary: "Many of ...
... Scientists at the Gladstone Institute of Cardiovascular Disease have ... drive the process of generating new heart cells. The ... Nature , provides important new directions on how ... For decades, scientists were unable to identify a ...
... novel approach for thwarting the relentless bacterial infections that ... (CF), unlocking new possibilities against a tenacious and toxic ... mainstay antibiotic with drugs to deprive the bacteria of ... infection killing, they found. Their research, reported in ...
Cached Biology News:Gladstone scientists identify key factors in heart cell creation 2Two-pronged model could help foil tough cystic fibrosis infections 2Two-pronged model could help foil tough cystic fibrosis infections 3
(Date:9/2/2015)... , Sept. 2, 2015 ... announced the addition of Jain PharmaBiotech,s new ... to their offering. ... pharmaceutical and biotechnology industries is anticipated. Nanotechnology ... drug development - from formulations for optimal ...
(Date:9/2/2015)... ARBOR, Mich. and LIBERTYVILLE, Ill. (PRWEB) , ... ... ... NSF International, a leading provider of regulatory compliance, quality systems, analytical ... Avarent LLC, a consulting firm with expertise in medical device products/processes development, ...
(Date:9/2/2015)... , Sep. 02, 2015 ... has announced the addition of Jain PharmaBiotech,s new ... Companies" to their offering. This ... development of sequencing technologies, and their applications. Current ... as companies developing them. Various applications of sequencing ...
(Date:9/2/2015)... Research and Markets ... Jain PharmaBiotech,s new report "Biochips and Microarrays ... offering. This report is an analysis ... The report starts with a description of technologies ... include array comparative genomic hybridization (CGH), copy number ...
Breaking Biology Technology:Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 3NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 2NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 3NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 4NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 5NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 6NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 7Global DNA Sequencing Technologies Report 2015: Profiles of 130 Companies Involved in Sequencing and their 140 Collaborations 2Global Biochips and Microarrays Technologies, Markets and Companies Report 2015 with Market Size in 2014 and Projected Value for the Years 2019 and 2024 2
... CEO Morhet to Discuss Continued Expansion of DXL(TM) Patent Protection ... ... Oct. 30 InNexus,Biotechnology Inc., (OTC Bulletin Board: IXSBF; TSX ... next,generation of monoclonal antibodies based on its Dynamic Cross Linking,(DXL(TM)) ...
... Calif., Oct. 30 Pharmacyclics,Inc. (Nasdaq: PCYC ) ... September 30, 2008. The net loss for the first ... share, compared to a net loss,of $6.8 million, or ... 2008., Total operating expenses were $6.6 million in ...
... ( http://www.oramed.com ), a developer of oral delivery,systems, announced ... be giving a company presentation at the 10th Annual ... Hotel on November,11. Mr. Kidron is scheduled to present ... on the 4th floor of the hotel., "The ...
Cached Biology Technology:InNexus Biotechnology Receives Patent Grants in Europe 2Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results 2Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results 3Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results 4Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results 5Oramed Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference (November 11, 2008; NYC) 2